Mark Stein, PhD, ABPP

Personal Statement

I am a Profesor of Psychiatry, Adjunct Professor of  Pediatrics, and a clinical researcher specializing in ADHD throughout the lifespan. I direct the PEARL Clinic (Program to enhance ​attention, regulation, and learning) at Seattle Children’s and Seattle Children’s at Overlake Hospital in Bellevue. The PEARL Clinic is based on a multidisciplinary and collaborative care model which works closely with PCP’s and schools. The majority of my clinical work involves  diagnostic evaluations and consultations. Treatment recommendations are made for the parents, referring physician, and schools. I also direct the clinical program for SEA STAR, a summer treatment program for children with ADHD and related disorders that targets social impairment and self-esteem, in collaboration with the UW Autism Center.

Comparative efficacy and personalized ADHD treatment are major themes of my work. I have published over 120 articles, mostly having to do with ADHD diagnosis and treatment in all ages, and specific areas within ADHD such as genetics, thyroid, and sleep . I have  participated in numerous clinical trials of stimulant  and non stimulant medications. Current research studies involve parents with ADHD, children with ADHD and Autism, and a new NIH sponsored study examining the effects of abruptly discontinuing methylphenidate in children with ADHD.

Other areas of interest include sleep problems and overlap with ADHD, pediatric psychology, and research ethics. Finally, I participate in the ITHS Treatment Innovatiopn Center, focusing on removing barriers to multi-site clinical and translational studies.

Department Affiliations

Recent Publications

Seizure risk, methylphenidate, and ADHD: reassuring news.
(2020 Jun)
Lancet Child Adolesc Health 4(6): 409-410
Russell D, Stein MA

Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial.
(2020 Feb 13)
Eur Urol Oncol
Bitting RL, Healy P, George DJ, Anand M, Kim S, Mayer T, Winters C, Riggan C, Rasmussen J, Wilder R, Stein M, Frizzell B, Harrison MR, Zhang T, Lee WR, Wu Y, Koontz BF, Armstrong AJ

Individual and joint effects of metformin and statins on mortality among patients with high-risk prostate cancer.
(2020 Apr)
Cancer Med 9(7): 2379-2389
Tan XL, E JY, Lin Y, Rebbeck TR, Lu SE, Shang M, Kelly WK, D'Amico A, Stein MN, Zhang L, Jang TL, Kim IY, Demissie K, Ferrari A, Lu-Yao G

Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy.
(2020 Mar)
Prostate 80(4): 336-344
Hawley JE, Pan S, Figg WD, Lopez-Bujanda ZA, Strope JD, Aggen DH, Dallos MC, Lim EA, Stein MN, Hu J, Drake CG

Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249).
(2019 Aug 7)
Kidney Cancer 3(2): 111-118
Synold TW, Plets M, Tangen CM, Heath EI, Palapattu GS, Mack PC, Stein MN, Meng MV, Lara P, Vogelzang NJ, Thompson IM, Ryan CW

Show complete publication list »